KIDNEY FUNCTION AFTER INITIATION AND DISCONTINUATION OF EMPAGLIFLOZIN IN HEART FAILURE PATIENTS WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE EMPERIAL TRIALS

被引：0
|
作者：
Sindone, A. [1 ]
Anker, S. D. [2 ]
Ponikowski, P. [3 ]
Wanner, C. [4 ]
Pfarr, E. [5 ]
Hauske, S. [6 ]
Peil, B. [5 ]
Salsali, A. [7 ]
Ritter, I. [8 ]
Nordaby, M. [6 ]
Koitka-Weber, A. [6 ]
Brueckmann, M. [6 ]
Jamal, W. [6 ]
Lindenfeld, J. [9 ]
Abraham, W. T. [10 ]
机构：
[1] Univ Sydney, Sch Med, Concord Clin Sch, Sydney, NSW, Australia
[2] Charite, Dept Cardiol, Berlin, Germany
[3] Wroclaw Med Univ, Dept Heart Dis, Wroclaw, Poland
[4] Wurzburg Univ Clin, Dept Med, Wurzburg, Germany
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat Data Sci, Ingelheim, Germany
[6] Boehringer Ingelheim Int GmbH, TA CardioMetab Resp Med, Ingelheim, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Clin Dev, Ingelheim, Germany
[8] Boehringer Ingelheim Int GmbH, Pharmacovigilance, Ingelheim, Germany
[9] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[10] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA
来源：
NEPHROLOGY | 2020年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [1] Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes Insights From the EMPERIAL Trials
    Anker, Stefan D.
    Ponikowski, Piotr
    Wanner, Christoph
    Pfarr, Egon
    Hauske, Sibylle
    Peil, Barbara
    Salsali, Afshin
    Ritter, Ivana
    Koitka-Weber, Audrey
    Brueckmann, Martina
    Lindenfeld, JoAnn
    Abraham, William T.
    CIRCULATION, 2021, 144 (15) : 1265 - 1267
  • [2] Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials (vol 144, pg 1265, 2021)
    Anker, Stefan D.
    CIRCULATION, 2022, 145 (08) : E641 - E641
  • [3] Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Emperial Trials
    Anker, Stefan D.
    Ponikowski, Piotr
    Wanner, Christoph
    Pfarr, Egon
    Hauske, Sibylle
    Peil, Barbara
    Salsali, Afshin
    Ritter, Ivana
    Nordaby, Matias
    Koitka-Weber, Audrey
    Brueckmann, Martina
    Jamal, Waheed
    Lindenfeld, JoAnn
    Abraham, William T.
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (12) : 1109 - 1109
  • [4] Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure
    Abraham, William T.
    Ponikowski, Piotr
    Brueckmann, Martina
    Zeller, Cordula
    Macesic, Hemani
    Peil, Barbara
    Brun, Michele
    Ustyugova, Anastasia
    Jamal, Waheed
    Salsali, Afshin
    Lindenfeld, Joann
    Anker, Stefan D.
    Abraham, William
    Anker, Stefan
    Lindenfeld, Joann
    Ponikowski, Piotr
    Brueckmann, Martina
    Salsali, Afshin
    Welty, Francine
    Clayton, Tim
    Greenberg, Barry
    Konstam, Marvin
    Lees, Kennedy
    Palmer, Mike
    Parhofer, Klaus
    Pedersen, Terje
    Carson, Peter
    Freston, James
    Kaplowitz, Neil
    Lewis, James
    Mann, Johannes
    Petrie, John
    Agostoni, Piergiuseppe
    Butler, Javed
    Desai, Akshay
    Filippatos, Gerasimos
    Howlett, Jonathan
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (07) : 932 - 942
  • [5] Mechanistic insights into the effects of empagliflozin in patients with type 2 diabetes and heart failure
    Elrakaybi, A.
    Laubner, K.
    Zhou, Q.
    Paeth, G.
    Schmitt, H.
    Hug, M. J.
    Seufert, J.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S24 - S24
  • [6] Design of the EMPERIAL trials of empagliflozin in patients with chronic heart failure with reduced or preserved ejection fraction
    Abraham, W. T.
    Anker, S. D.
    Salsali, A.
    Peil, B.
    Zeller, C.
    Brun, M.
    Macesic, H.
    Brueckmann, M.
    Lindenfeld, J.
    Ponikowski, P.
    DIABETOLOGIA, 2018, 61 : S323 - S324
  • [7] Empagliflozin decreases risk of kidney function decline in type 2 diabetes: slope analyses in patients with / without heart failure at baseline from the EMPA-REG OUTCOME trial
    Cheung, A. K.
    Fitchett, D.
    Zinman, B.
    Anker, S. D.
    Broedl, U. C.
    Salsali, A.
    Mattheus, M.
    von Eynatten, M.
    Wanner, C.
    DIABETOLOGIA, 2017, 60 : S427 - S427
  • [8] Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure Insights From the EMPA-REG OUTCOME Trial
    Butler, Javed
    Zannad, Faiez
    Fitchett, David
    Zinman, Bernard
    Koitka-Weber, Audrey
    von Eynatten, Maximilian
    Zwiener, Isabella
    George, Jyothis
    Brueckmann, Martina
    Cheung, Alfred K.
    Wanner, Christoph
    CIRCULATION-HEART FAILURE, 2019, 12 (06)
  • [9] Empagliflozin and kidney outcomes in patients with or without heart failure at baseline: insights from the EMPA-REG OUTCOME trial
    Butler, J.
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    DIABETOLOGIA, 2018, 61 : S323 - S323
  • [10] Empagliflozin in the treatment of heart failure and type 2 diabetes mellitus: Evidence from several large clinical trials
    Liang, Bo
    Gu, Ning
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2022, 19 (07): : 1118 - 1121
12345